Why the FDA's Decision on Aimmune's Peanut Allergy Drug Is Crucial for the Company -- and Patients

Why the FDA's Decision on Aimmune's Peanut Allergy Drug Is Crucial for the Company -- and Patients

Source: 
Motley Fool
snippet: 

Aimmune Therapeutics' (NASDAQ: AIMT) share price has gained 11% over the past month as the company waits for the Food and Drug Administration to issue an approval decision on its very first drug, one that represents the theme of its three-drug pipeline: treatments to address food allergies.